文献速递外周动脉疾病

术前炎症状态可预测股腘动脉支架植入后一期通畅率

Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation.
PubMed 文献 · J Vasc Surg · 2017-03-01

该回顾性研究纳入138例首次股腘动脉支架植入患者,按术前血常规参数三分位分组,评估术前炎症状态与12及24个月支架内再狭窄导致一期通畅率丢失的关系。结果显示术前白细胞、血小板和中性粒细胞计数升高与ISR风险增加独立相关,而淋巴细胞分组无显著差异。

要点

  • 术前白细胞、血小板、中性粒细胞计数升高与股腘动脉支架ISR风险增加独立相关。
  • 上三分位白细胞组中位通畅期7.0个月,校正后ISR风险增加3.3倍。
  • 术前血常规或可用于股腘动脉支架术后ISR风险分层。

核心结论

  • 术前血常规反映的基线炎症状态可能有助于股腘动脉支架术后ISR的风险分层。
  • 循环白细胞、血小板和中性粒细胞可能是ISR的重要炎症介质。

研究设计与样本

  • 回顾性分析2005至2014年单中心138例首次股腘动脉支架植入患者,中位年龄73岁,女性46%,术前有血常规且术后至少12个月通畅信息。
  • 按术前血常规参数三分位分组,评估与ISR导致一期通畅率丢失的关联。
  • ISR定义:多普勒流速比≥2.5:1、CTA示支架内管腔狭窄≥50%或再干预。

主要发现

  • 12个月内发生ISR的81例(59%)术前白细胞、血小板、中性粒细胞和淋巴细胞计数均显著高于57例(41%)支架保持通畅超过12个月者(分别为8.7 vs 6.7,P < .001;246 vs 184,P < .001;5.7 vs 4.7,P = .001;1.8 vs 1.2,P = .004)。
  • 上三分位白细胞组(n = 44)中位通畅期7.0个月,低于下三分位组(n = 45)的19.4个月,多因素校正后ISR风险增加3.3倍(P < .001)。
  • 上三分位血小板组(n = 47)中位通畅期7.1个月,低于下三分位组(n = 45)的16.9个月,校正后风险增加2.7倍(P = .001)。
  • 上三分位中性粒细胞组(n = 33)中位通畅期6.2个月,低于下三分位组(n = 33)的14.3个月,校正后风险增加3.2倍(P = .001)。
  • 按淋巴细胞计数三分位分组者校正协变量后ISR无显著差异。

临床怎么用

  • 可利用常规术前血常规中的白细胞、血小板和中性粒细胞计数辅助识别股腘动脉支架术后ISR高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to evaluate the impact of preoperative inflammatory status, as determined by complete blood count test parameters, on 12- and 24-month patency of femoropopliteal stenting for peripheral arterial disease. METHODS: We retrospectively analyzed baseline clinical and angiographic data among 138 patients (median age, 73 years; 46% female) from 2005 to 2014 at our institution with preoperative complete blood count test values and information of patency for at least 12 months after first-time femoropopliteal stenting. Patients were stratified into tertiles on the basis of preoperative blood counts to evaluate associations with in-stent restenosis (ISR) leading to loss of primary patency, defined by a Doppler velocity ratio ≥2.5:1, computed tomography angiography demonstrating ≥50% luminal narrowing within the stent, or reintervention. RESULTS: Univariate analysis determined that the 81 patients (59%) who experienced ISR within 12 months had significantly higher preoperative white blood cell (WBC), platelet, neutrophil, and lymphocyte counts than the 57 patients (41%) whose stents remained patent for longer than 12 months (8.7 vs 6.7 [P < .001], 246 vs 184 [P < .001], 5.7 vs 4.7 [P = .001], and 1.8 vs 1.2 [P = .004], respectively). Compared with patients in the lower WBC tertile (n = 45) who had a median patency of 19.4 months, those in the upper WBC tertile (n = 44) had a median patency of only 7.0 months and a 3.3-fold increased risk for ISR after adjusting for age, sex, lesion type, TransAtlantic Inter-Society Consensus II score, tibial vessel runoff, antiplatelet therapy, presence of diabetes, critical limb ischemia, adjunct procedures, hyperlipidemia, and end-stage renal disease in multivariate analysis (P < .001). Compared with patients in the lower platelet tertile (n = 45) who had a median patency of 16.9 months, those in the upper platelet tertile (n = 47) had a median patency of 7.1 months and a 2.7-fold increased adjusted risk (P = .001). Compared with patients in the lower neutrophil tertile (n = 33) who had a median patency of 14.3 months, those in the upper neutrophil tertile (n = 33) had a median patency of 6.2 months and a 3.2-fold increased adjusted risk (P = .001). After adjusting for covariates, patients divided into tertiles by lymphocyte counts exhibited no significant differences for ISR. CONCLUSIONS: Routine preoperative tests that determine baseline inflammatory status may provide strong clinical utility in assessing potential risk stratification of patients for ISR after femoropopliteal stenting. Circulating WBCs, platelets, and neutrophils may be important inflammatory mediators of ISR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nakazawa KR, Wengerter SP, Power JR, et al. Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation. J Vasc Surg. 2017. PMID: 28259571. doi:10.1016/j.jvs.2017.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。